Percheron Therapeutics Limited (ASX: PER)
Health Care · Pharmaceuticals · AU
AU$0.00
-11.11% today · -60.0% 1Y
Percheron Therapeutics Limited (ASX: PER) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.07M and employs 8 people.
Over the last twelve months the share price has lost 60.0%, trading between 0.00 and 0.01.
Tweenvest scores Percheron Therapeutics Limited across four factors: quality 37/100, value 53/100. Its strongest factor is value.
PER price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.07M
- Revenue (TTM)
- $583.60K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 1.13
- 52-week high
- AU$0.01
- 52-week low
- AU$0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.82B
- Employees
- 8
- Next earnings
- —
About Percheron Therapeutics Limited
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limited until its name change in December 2023, the company holds a promising product portfolio. This includes ATL1102, an antisense inhibitor designed to target CD49d, which is currently undergoing Phase IIa clinical trials for the treatment of various inflammatory and muscular conditions such as Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, and asthma. Another key asset is Atesidorsen (ATL1103), an oligonucleotide that has finished Phase II clinical trials. Atesidorsen functions by blocking the growth hormone receptor, aiming to lower blood concentrations of insulin-like growth factor-I (IGF-I) and thereby address illnesses linked to an overabundance of growth hormone activity.
- ISIN
- AU0000317281
- Founded
- 2000
- Listed since
- Dec 26, 2023
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cann Group LimitedASX: CAN | $5.19M | AU$0.00 | -10.00% |
| OncoZenge AB (publ)OM: ONCOZ | $5.19M | Skr3.32 | -5.55% |
| Rua Bioscience LimitedNZSE: RUA | $5.14M | NZ$0.03 | -6.90% |
| cbdMD, Inc.NYSEAM: YCBD | $5.11M | $0.41 | -10.75% |
| Panacea Life Sciences Holdings, Inc.OTCPK: PLSH | $5.06M | $0.09 | +6.25% |
| Biofil Chemicals and Pharmaceuticals LimitedBSE: 524396 | $5.01M | Rs29.64 | -9.50% |
| Enorama Pharma AB (publ)OM: ERMA | $4.97M | Skr0.61 | -8.96% |
| Vivimed Labs LimitedNSEI: VIVIMEDLAB | $4.92M | Rs5.71 | +2.88% |
Figures last refreshed Oct 4, 2026.